Clinical trial

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

NCT06693024

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2019-01-01

PhaseN/A

Study timeline

Study start (actual)2019-01-01Date precision: day

Registry last updated2024-11-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

Interventions

neratinibDRUG · verified · RxNorm: neratinib

Sponsors & collaborators

Shu Wanglead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06693024 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.